Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
M MUSCULO-SKELETAL SYSTEM
M05 DRUGS FOR TREATMENT OF BONE DISEASES
M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
M05BA Bisphosphonates
M05BA06 Ibandronic acid
D04486 Ibandronate sodium (USAN) <JP/US>
USP drug classification [BR:br08302]
Metabolic Bone Disease Agents
Bisphosphonates
Ibandronate
D04486 Ibandronate sodium (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D04486 Ibandronate sodium (USAN); Ibandronate sodium hydrate (JAN)
Drug groups [BR:br08330]
Musculo-skeletal system agent
DG03232 Osteoporosis agent
DG01600 Bisphosphonate
DG00785 Ibandronic acid
D04486 Ibandronate sodium
Drug classes [BR:br08332]
Musculo-skeletal system agent
DG03232 Osteoporosis agent
D04486 Ibandronate sodium
Target-based classification of drugs [BR:br08310]
Enzymes
Transferases (EC2)
Alkyl/Aryl transferases
FDPS
D04486 Ibandronate sodium (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D04486
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D04486
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D04486
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D04486
Drug groups [BR:br08330]
Musculo-skeletal system agent
DG03232 Osteoporosis agent
DG01600 Bisphosphonate
DG00785 Ibandronic acid